Biopharma's Technology and Capital Partner
Technology and financing solutions to advance tomorrow’s medicines
in healthcare investing
Our portfolio includes programs that span disease areas such as cancer, kidney disease, diabetes, nonalcoholic steatohepatitis, and many rare conditions. Today we own economic rights to more than 25 commercial programs, which are marketed in more than 70 countries.
By the Numbers
and Q4 2023
Ligand Acquires Royalties on Sanofi’s TZIELD®
Ligand acquires Tolerance Therapeutics for $20 million in cash including a royalty of less than 1% on worldwide net sales of TZIELD®.
Ovid Therapeutics and Ligand Enter into $30 Million Agreement
Ligand acquires royalties and milestones on Takeda’s soticlestat, a potential treatment for Lennox-Gastaut syndrome and Dravet syndrome.
Ligand Pelican Subsidiary Merged with Primordial Genetics
Ligand spins out Pelican subsidiary, retains all commercial royalties and now owns 49.9% of Primrose Bio.